2022 American Transplant Congress
The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease Following Lung Transplantation: A Retrospective Analysis from a Single Transplantation Center
*Purpose: Chronic kidney disease (CKD) is a progressive and irreversible complication in lung transplant patients who have received long-term treatment with tacrolimus. This study aimed…2022 American Transplant Congress
Influence of Converting Kidney Transplant Recipients with High Tacrolimus Variability to the Once Daily LCP Tac Formulation
Med Univ of South Carolina, Charleston, SC
*Purpose: Tacrolimus (Tac) is the cornerstone of immunosuppression used in kidney transplant recipients (KTRs). Tac high variability, low time in therapeutic range and non-adherence are…2022 American Transplant Congress
The Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation
*Purpose: This study aimed to evaluate the association of tacrolimus coefficient of variation (CV) with biopsy-proven acute cellular rejection in the first year following lung…2022 American Transplant Congress
Impact of Sub-therapeutic Tacrolimus Troughs at Discharge from Index Admission on Short-Term Outcomes in Kidney Transplant Recipients Receiving Rabbit Anti-Thymocyte Globulin Induction
*Purpose: Kidney transplant (KTx) recipients are often discharged with subtherapeutic tacrolimus (TAC) troughs due to short hospital lengths of stay (LOS) for index KTx admissions.…2022 American Transplant Congress
Prevention of the Progression in Chronic Calcineurin Inhibitors Nephrotoxicity via Steroids Anti-Inflammatory Effects
*Purpose: Calcineurin inhibitors (CNI) lead to an excellent short-term kidney allograft outcome. However, chronic nephrotoxicity is a major concern, which affects a long-term allograft survival.…2022 American Transplant Congress
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
*Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »